Our most immediate challenges are the identification of relatives of patients with a strong predisposition to illness, analysis and cross-referencing of omics data, improvement of the most innovative cell therapies, collaboration between EU partners and the creation of an operational infrastructure between the Institutes associated with ACC to foster clinical and translational academic research.

There are five programs with which the network is currently engaged. The first concerns genomics oncology, for which the Gersom platform has been developed to decode tumours and identify patients who have fallen ill due to a strong genetic predisposition. On top of allowing better care, the program will make it possible to identify healthy family members at high risk of developing cancer and send those in need to suitable prevention paths, thus saving many lives.

The second, Health Big Data, strategic for the whole SSN, analyzes conventional clinical data and integrates them with others deriving from the omics sciences. The third is related to Car-T therapies: ACC, together with the most advanced Italian centers in this field, will develop new treatments with CAR-T cells programmed to destroy tumours that are not effectively treatable in another way. The fourth, Forza, aims to create an operational infrastructure among the 28 Institutes associated with ACC to foster clinical and translational academic research. The fifth, Transcan, promotes and finances new translational research projects between EU partners.